VYNE Therapeutics Doses First Volunteers In Phase 1a Trial Of VYN202; Oral BET Inhibitor Targeting Immuno-Inflammatory Diseases; Top-Line Data Expected In H2 2024
VYNE Therapeutics Doses First Volunteers In Phase 1a Trial Of VYN202; Oral BET Inhibitor Targeting Immuno-Inflammatory Diseases; Top-Line Data Expected In H2 2024
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.